Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 176.75
ABAX's Cash to Debt is ranked higher than
72% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.07 vs. ABAX: 176.75 )
ABAX' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 176.75

Equity to Asset 0.89
ABAX's Equity to Asset is ranked higher than
94% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. ABAX: 0.89 )
ABAX' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.9
Current: 0.89

0.51
0.9
F-Score: 6
Z-Score: 30.11
M-Score: -3.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 12.10
ABAX's Operating margin (%) is ranked higher than
87% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.84 vs. ABAX: 12.10 )
ABAX' s 10-Year Operating margin (%) Range
Min: -930   Max: 22.65
Current: 12.1

-930
22.65
Net-margin (%) 8.25
ABAX's Net-margin (%) is ranked higher than
83% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. ABAX: 8.25 )
ABAX' s 10-Year Net-margin (%) Range
Min: -900   Max: 51.27
Current: 8.25

-900
51.27
ROE (%) 7.32
ABAX's ROE (%) is ranked higher than
72% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. ABAX: 7.32 )
ABAX' s 10-Year ROE (%) Range
Min: -86.54   Max: 44.04
Current: 7.32

-86.54
44.04
ROA (%) 6.54
ABAX's ROA (%) is ranked higher than
81% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. ABAX: 6.54 )
ABAX' s 10-Year ROA (%) Range
Min: -74.38   Max: 38.83
Current: 6.54

-74.38
38.83
ROC (Joel Greenblatt) (%) 28.48
ABAX's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. ABAX: 28.48 )
ABAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -198.89   Max: 52.66
Current: 28.48

-198.89
52.66
Revenue Growth (%) 6.60
ABAX's Revenue Growth (%) is ranked higher than
72% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. ABAX: 6.60 )
ABAX' s 10-Year Revenue Growth (%) Range
Min: 6.6   Max: 93.9
Current: 6.6

6.6
93.9
EBITDA Growth (%) -8.00
ABAX's EBITDA Growth (%) is ranked higher than
62% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. ABAX: -8.00 )
ABAX' s 10-Year EBITDA Growth (%) Range
Min: -33.7   Max: 171.4
Current: -8

-33.7
171.4
EPS Growth (%) -0.50
ABAX's EPS Growth (%) is ranked higher than
69% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ABAX: -0.50 )
ABAX' s 10-Year EPS Growth (%) Range
Min: -59.2   Max: 159.6
Current: -0.5

-59.2
159.6
» ABAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ABAX Guru Trades in Q2 2013

Steven Cohen 62,500 sh (New)
RS Investment Management 467,780 sh (New)
Chuck Royce 323,100 sh (+10.16%)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q3 2013

ABAX Guru Trades in Q3 2013

Jim Simons 37,971 sh (New)
Steven Cohen Sold Out
RS Investment Management Sold Out
Chuck Royce 300 sh (-99.91%)
» More
Q4 2013

ABAX Guru Trades in Q4 2013

PRIMECAP Management 575,000 sh (New)
Joel Greenblatt 25,721 sh (New)
Jim Simons 100,869 sh (+165.65%)
Chuck Royce Sold Out
» More
Q1 2014

ABAX Guru Trades in Q1 2014

PRIMECAP Management 1,979,300 sh (+244.23%)
Jim Simons Sold Out
Joel Greenblatt 20,229 sh (-21.35%)
» More
» Details

Insider Trades

Latest Guru Trades with ABAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-03-31 Add 244.23%0.06%$36.29 - $45.01 $ 46.9818%1979300
Joel Greenblatt 2014-03-31 Reduce -21.35%0.01%$36.29 - $45.01 $ 46.9818%20229
PRIMECAP Management 2013-12-31 New Buy0.03%$32.4 - $41.25 $ 46.9828%575000
Joel Greenblatt 2013-12-31 New Buy0.02%$32.4 - $41.25 $ 46.9828%25721
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 74.40
ABAX's P/E(ttm) is ranked higher than
75% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 74.40 )
ABAX' s 10-Year P/E(ttm) Range
Min: 10.19   Max: 148.82
Current: 74.4

10.19
148.82
P/B 5.50
ABAX's P/B is ranked higher than
66% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.83 vs. ABAX: 5.50 )
ABAX' s 10-Year P/B Range
Min: 2.19   Max: 14.35
Current: 5.5

2.19
14.35
P/S 6.20
ABAX's P/S is ranked higher than
65% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.41 vs. ABAX: 6.20 )
ABAX' s 10-Year P/S Range
Min: 2.48   Max: 9.5
Current: 6.2

2.48
9.5
PFCF 35.20
ABAX's PFCF is ranked higher than
85% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 35.20 )
ABAX' s 10-Year PFCF Range
Min: 21.92   Max: 101.52
Current: 35.2

21.92
101.52
EV-to-EBIT 46.33
ABAX's EV-to-EBIT is ranked higher than
77% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 46.33 )
ABAX' s 10-Year EV-to-EBIT Range
Min: 10.6   Max: 118.6
Current: 46.33

10.6
118.6
PEG 41.60
ABAX's PEG is ranked higher than
85% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 41.60 )
ABAX' s 10-Year PEG Range
Min: 0.7   Max: 42.4
Current: 41.6

0.7
42.4
Shiller P/E 63.50
ABAX's Shiller P/E is ranked higher than
89% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 63.50 )
ABAX' s 10-Year Shiller P/E Range
Min: 21.13   Max: 317.57
Current: 63.5

21.13
317.57
Current Ratio 9.81
ABAX's Current Ratio is ranked higher than
93% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. ABAX: 9.81 )
ABAX' s 10-Year Current Ratio Range
Min: 1.67   Max: 9.82
Current: 9.81

1.67
9.82
Quick Ratio 8.21
ABAX's Quick Ratio is ranked higher than
93% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.48 vs. ABAX: 8.21 )
ABAX' s 10-Year Quick Ratio Range
Min: 1.19   Max: 8.45
Current: 8.21

1.19
8.45

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.20
ABAX's Dividend Yield is ranked lower than
90% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.25 vs. ABAX: 0.20 )
ABAX' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 0.2

Yield on cost (5-Year) 0.20
ABAX's Yield on cost (5-Year) is ranked lower than
88% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. ABAX: 0.20 )
ABAX' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 0.2

Share Buyback Rate 0.40
ABAX's Share Buyback Rate is ranked higher than
92% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.70 vs. ABAX: 0.40 )
ABAX' s 10-Year Share Buyback Rate Range
Min: 0.4   Max: -18
Current: 0.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.20
ABAX's Price/Net Cash is ranked higher than
86% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 13.20 )
ABAX' s 10-Year Price/Net Cash Range
Min: 6.71   Max: 190.5
Current: 13.2

6.71
190.5
Price/Net Current Asset Value 9.20
ABAX's Price/Net Current Asset Value is ranked higher than
87% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 9.20 )
ABAX' s 10-Year Price/Net Current Asset Value Range
Min: 4.68   Max: 279.17
Current: 9.2

4.68
279.17
Price/Tangible Book 5.50
ABAX's Price/Tangible Book is ranked higher than
74% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.75 vs. ABAX: 5.50 )
ABAX' s 10-Year Price/Tangible Book Range
Min: 2.86   Max: 16.11
Current: 5.5

2.86
16.11
Price/DCF (Projected) 2.80
ABAX's Price/DCF (Projected) is ranked higher than
84% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 2.80 )
ABAX' s 10-Year Price/DCF (Projected) Range
Min: 1.85   Max: 16.52
Current: 2.8

1.85
16.52
Price/Median PS Value 1.30
ABAX's Price/Median PS Value is ranked higher than
76% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. ABAX: 1.30 )
ABAX' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 7.12
Current: 1.3

0.31
7.12
Price/Peter Lynch Fair Value 6.90
ABAX's Price/Peter Lynch Fair Value is ranked higher than
89% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 6.90 )
ABAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.76   Max: 37.65
Current: 6.9

0.76
37.65
Price/Graham Number 4.30
ABAX's Price/Graham Number is ranked higher than
81% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 4.30 )
ABAX' s 10-Year Price/Graham Number Range
Min: 2.08   Max: 10.19
Current: 4.3

2.08
10.19
Earnings Yield (Greenblatt) 2.20
ABAX's Earnings Yield (Greenblatt) is ranked higher than
52% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ABAX: 2.20 )
ABAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 9.5
Current: 2.2

0.8
9.5
Forward Rate of Return (Yacktman) 12.30
ABAX's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.81 vs. ABAX: 12.30 )
ABAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2   Max: 43.2
Current: 12.3

-2
43.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AXS.Germany
Abaxis, Inc. was incorporated in California in 1989. The Company develops, manufactures, markets and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. It offers point-of-care blood chemistry analyzer, which consists of a compact portable analyzer and a series of single-use plastic discs, called reagent discs, containing all the chemicals required to perform a panel of up to 14 tests on human patients and 13 tests on veterinary patients. The Company markets the blood analysis systems under the Piccolo Xpress, Piccolo Classic, VetScan VS2, and VetScan Classic names. The Company also provides VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, it offers VetScan VSpro, which assists in the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, evaluation of disseminated intravascular coagulation, hepatic disease, monitoring therapy, and the progression of disease states; VetScan VSpro fibrinogen test to provide in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; and i-STAT 1 that delivers blood gas, electrolyte, basic blood chemistry, and hematology results. Further, the company provides Canin Heartworm rapid test to detect dirofilaria immitis in canine whole blood, serum, or plasma; Canine Parvovirus rapid test to detect canine parvovirus antigen in feces; VetScan Giardia rapid test to detect giardiasis, a gastrointestinal infection caused by the protozoan parasite Giardia; and Canine Lyme rapid test to detect Borrelia burgdorferi in canine whole blood, serum, or plasma. Additionally, it offers veterinary reference laboratory diagnostic and consulting services. The Company sells its products through direct sales force and independent distributors.
» More Articles for ABAX

Headlines

Articles On GuruFocus.com
ABAXIS Inc. (ABAX) COO Donald Peter Wood sells 6,460 Shares Mar 08 2011 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 35,000 Shares Dec 10 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 96,000 Shares Dec 08 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 66,029 Shares Dec 07 2010 
ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. Jan 13 2009 


More From Other Websites
Haemonetics Tops Q1 Earnings and Revenues, Guidance Retained Aug 01 2014
Abaxis (ABAX) Soars: Stock Rises 9% Jul 28 2014
Abaxis Rebounds with Q1 Earnings Beat, Revenues Up Y/Y Jul 25 2014
ABAXIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Jul 24 2014
Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 Jul 24 2014
Q1 2015 ABAXIS INC Earnings Release - After Market Close Jul 24 2014
Abaxis To Report First Quarter Fiscal Year 2015 Financial Results Thursday, July 24, 2014 Jul 17 2014
Abaxis' VetScan Test Kit Wins USDA Approval Jul 02 2014
Abaxis, Inc. Announces USDA Approval of VetScan Canine Ehrlichia Antibody Test Kit Jul 01 2014
Abaxis, Inc. Announces USDA Approval of VetScan Canine Ehrlichia Antibody Test Kit Jul 01 2014
Abaxis: Updated Research Report Jun 18 2014
ABAXIS INC Financials Jun 06 2014
ABAXIS INC Files SEC form 10-K, Annual Report May 30 2014
Stifel to hold a conference May 28 2014
Abaxis, Inc. to Present at the Jefferies 2014 Global Healthcare Conference May 27 2014
Abaxis, Inc. to Present at the Stifel Dental & Veterinary Conference May 21 2014
Abaxis, VCA Antech Ink Twin Deal May 14 2014
VCA Inc. and Abaxis, Inc. Announce Long-Term Product Supply Agreement and a Co-Marketing Agreement... May 12 2014
Abaxis, VCA Antech annonce long-term supply, marketing agreement May 12 2014
Abaxis, Inc. and VCA Inc. Announce Long-Term Product Supply Agreement and a Co-Marketing Agreement... May 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide